Income Statement (TTM)
Navidea Biopharmaceuticals, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 09-30 |
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change (%) | 12.26 | -3.56 | -1.14 | -19.72 | -24.11 | -23.28 | -49.91 | -43.51 | -43.10 | 0.00 | -87.62 | -92.49 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Change (%) | -9.34 | -58.11 | -81.32 | -100.00 | 28,422.41 | 37.09 | 0.00 | -0.26 | -72.88 | ||||
| % of Revenue | 0.14 | 0.11 | 0.05 | 0.01 | 0.00 | 0.23 | 116.92 | 281.71 | 281.71 | 2,270.17 | 8,202.62 | ||
| Gross Operating Profit | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | -0 | -0 | -0 | -0 | -0 |
| Change (%) | 12.29 | -3.49 | -1.10 | -19.71 | -24.11 | -23.28 | -50.03 | -109.58 | 511.11 | -0.00 | 47.83 | -71.97 | |
| % of Revenue | 99.86 | 99.89 | 99.95 | 99.99 | 100.00 | 100.00 | 100.00 | 99.77 | -16.92 | -181.71 | -181.71 | -2,170.17 | -8,102.62 |
| SG&A | 6 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 6 | 5 | 5 | 5 | 5 |
| Change (%) | 9.54 | 6.02 | 1.45 | -4.44 | 8.26 | -6.29 | -2.74 | -6.34 | -15.69 | -11.34 | 1.67 | 5.47 | |
| % of Revenue | 749.89 | 731.68 | 804.32 | 825.40 | 982.47 | 1,401.66 | 1,712.10 | 3,324.24 | 5,511.25 | 8,167.04 | 7,241.24 | 59,481.80 | 835,697.54 |
| R&D | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 5 | 5 |
| Change (%) | -8.44 | 4.53 | 4.20 | -6.13 | 2.01 | -1.04 | 4.44 | 2.59 | 9.50 | 1.64 | -10.18 | -6.55 | |
| % of Revenue | 660.63 | 538.81 | 584.00 | 615.52 | 719.68 | 967.41 | 1,247.84 | 2,601.80 | 4,724.82 | 9,093.06 | 9,242.63 | 67,071.75 | 834,990.82 |
| OpEx | 11 | 12 | 12 | 13 | 12 | 13 | 12 | 12 | 12 | 12 | 11 | 10 | 10 |
| Change (%) | 1.12 | 5.38 | 2.60 | -5.16 | 5.62 | -4.15 | 0.29 | -1.31 | -3.60 | -4.43 | -4.89 | -2.17 | |
| % of Revenue | 1,410.66 | 1,270.60 | 1,388.37 | 1,440.93 | 1,702.15 | 2,369.07 | 2,959.94 | 5,926.28 | 10,352.99 | 17,541.81 | 16,765.58 | 128,823.78 | 1,678,891.80 |
| Operating Income | -11 | -11 | -11 | -12 | -11 | -12 | -12 | -12 | -12 | -11 | -11 | -10 | -10 |
| Change (%) | 0.27 | 6.15 | 2.89 | -4.08 | 7.47 | -3.30 | 2.04 | -0.58 | -3.21 | -4.45 | -4.40 | -2.10 | |
| % of Revenue | -1,310.66 | -1,170.60 | -1,288.37 | -1,340.93 | -1,602.15 | -2,269.07 | -2,859.94 | -5,826.28 | -10,252.99 | -17,441.81 | -16,665.57 | -128,723.73 | -1,678,790.16 |
| Interest Expense | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -0 | -1 | -1 | |
| Change (%) | -0.00 | -1.79 | -12.73 | 50.00 | -0.00 | 8.74 | 843.17 | 825.92 | -60.81 | 77.47 | -5.82 | ||
| % of Revenue | -0.86 | -0.77 | -0.78 | -0.69 | -1.28 | -1.69 | -2.40 | -45.19 | -740.71 | -510.27 | -905.58 | -6,890.49 | |
| Net Income | -11 | -11 | -11 | -11 | -11 | -12 | -12 | -12 | -15 | -15 | -14 | -5 | -1 |
| Change (%) | 0.48 | 2.74 | 3.16 | -4.06 | 7.60 | 0.17 | 2.77 | 27.08 | -1.10 | -9.96 | -66.08 | -74.49 | |
| % of Revenue | -1,309.16 | -1,171.75 | -1,248.19 | -1,302.51 | -1,556.49 | -2,207.08 | -2,881.80 | -5,912.53 | -13,299.84 | -23,117.57 | -20,816.18 | -57,038.72 | -193,848.85 |
Source: Capital IQ
